Sanofi SA
SNY
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
Can you achieve global diversification with multinational companies?
A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,321.10 | 10.80 | -0.12% |
| CAC 40 | 8,243.84 | 15.02 | -0.18% |
| DAX 40 | 24,316.25 | 13.78 | -0.06% |
| Dow JONES (US) | 46,924.74 | 218.16 | 0.47% |
| FTSE 100 | 9,514.32 | 87.33 | 0.93% |
| HKSE | 25,781.77 | 245.78 | -0.94% |
| NASDAQ | 22,953.67 | 36.88 | -0.16% |
| Nikkei 225 | 49,307.79 | 8.27 | -0.02% |
| NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
| S&P 500 | 6,735.35 | 0.22 | 0.00% |
| S&P/ASX 200 | 9,030.00 | 10.30 | -0.11% |
| SSE Composite Index | 3,913.76 | 2.57 | -0.07% |